Flu Fighter Visterra Tops Up Series A Round With Cash From Gates
This article was originally published in The Pink Sheet Daily
Executive Summary
To help push an antibody flu treatment into the clinic, the biotech has added $13 million from The Gates Foundation and others to bring total Series A funding to $26 million.